Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 4, 2011, Pages 424-433

  Warren, Jeffrey S ^a   Zhao, Ying ^a   Yung, Raymond ^a   Desai, Anjali ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

apolipoprotein E deficient mice; apoptosis; Atherosclerosis; Bax; Bcl 2; erythropoietin

Indexed keywords

APOLIPOPROTEIN; DNA FRAGMENT; GENISTEIN; LIPOPOLYSACCHARIDE; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIAL CELL APOPTOSIS; ENDOTHELIUM CELL; FLOW CYTOMETRY; IN VIVO STUDY; LIPOPROTEIN DEFICIENCY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; AORTA; APOLIPOPROTEINS E; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; DIETARY FATS; ENDOTHELIAL CELLS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ERYTHROPOIETIN; UP-REGULATION;

EID: 79955030143     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31820d92fd     Document Type: Article

References (58)

1. Wheeler DC Cardiovascular disease in patients with chronic renal failure. Lancet. 1996;348:1673-1674. (Pubitemid 27007525)
2. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. (Pubitemid 44749317)
3. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361: 2019-2032.
4. Desai A, Zhao Y, Lankford HA, et al. Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest. 2006;86:369-379.
5. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension. 1999;33:894-899. (Pubitemid 29140452)
6. Filippatos G, Ang E, Gidea C, et al. Fas induces apoptosis in human coronary artery endothelial cells in vitro. BMC Cell Biol. 2004;5:6.
7. Choy JC, Granville DJ, Hunt DW, et al. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001;33:1673-1690. (Pubitemid 32844225)
8. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb VascBiol. 2002;22:1370-1380.
9. Dimmeler S, Haendeler J, Zeiher AM Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol. 2002;13:531-536. (Pubitemid 35231933)
10. Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood. 1999;93: 3831-3838. (Pubitemid 29249830)
11. Tsujimoto Y Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep. 2002;22:47-58. (Pubitemid 35217479)
12. Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c Nature. 1998;391:496-499. (Pubitemid 28086551)
13. Dong C, Granville DJ, Tuffnel CE, et al. Bax and apoptosis in acute and chronic rejection of rat cardiac allografts. Lab Invest. 1999;79:1643-1653. (Pubitemid 30013928)
14. Bannerman DD, Goldblum SE. Mechanisms ofbacterial lipopolysaccha-ride- induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol. 2003;284:L899-L914. (Pubitemid 36687124)
15. Kim KY, Shin HK, Choi JM, et al. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther. 2002;300:709-715.
16. Susin SA, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. JExp Med. 1996;184:1331-1341. (Pubitemid 26354689)
17. Haendeler J, Zeiher AM, Dimmeler S. Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur J Pharmacol. 1996;317:407-411. (Pubitemid 27014049)
18. Molostvov G, Morris A, Rose P, et al. Modulation of Bcl-2 family proteins in primary endothelial cells during apoptosis. Pathophysiol Haemost Thromb. 2002;32:85-91. (Pubitemid 37490512)
19. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576-1582. (Pubitemid 26307051)
20. Carlini RG, Alonzo EJ, Dominguez J, et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int. 1999;55: 546-553. (Pubitemid 29082880)
21. Sekiguchi N, Inoguchi T, Kobayashi K, et al. Effect of erythropoietin on endothelial cell apoptosis induced by high glucose. Diabetes Res Clin Pract. 2004;66(Suppl 1):S103-S107. (Pubitemid 39572594)
22. Sekiguchi N, Inoguchi T, Kobayashi K, et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun. 2005;334:218-222. (Pubitemid 40978528)
23. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973-2979. (Pubitemid 35424751)
24. Bieber E. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. J Reprod Med. 2001;46(5 suppl):521-530. (Pubitemid 32489123)
25. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273: 458-464.
26. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer. 2005;93:1350-1355. (Pubitemid 41752861)
27. Katz O, Barzilay E, Skaat A, et al. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol. 2005; 114:177-179. (Pubitemid 41540345)
28. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA. 2001;98:5181-5186. (Pubitemid 32397103)
29. Desai A, Zhao Y Warren JS. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant. 2008;23:1513-1520. (Pubitemid 351767760)
30. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996;273:464-471. (Pubitemid 26286442)
31. Kawakami M, Iwasaki S, Sato K, et al. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun. 2000;279:293-297.
32. Desai A, Miller MJ, Gomez HF, et al. Loxosceles deserta spider venom induces NF-kappaB-dependent chemokine production by endothelial cells. J Toxicol Clin Toxicol. 1999;37:447-456. (Pubitemid 29387888)
33. Desai A, Zhao Y, Warren JS. Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice. Cardiovasc Pathol. 2008;17: 233-240. (Pubitemid 351978279)
34. Desai A, Miller MJ, Huang X, et al. Nitric oxide modulates MCP-1 expression in endothelial cells: implications for the pathogenesis of pulmonary granulomatous vasculitis. Inflammation. 2003;27: 213-223. (Pubitemid 37034469)
35. Vogel V, Kramer HJ, Backer A, et al. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am JHypertens. 1997;10:289-296. (Pubitemid 27128272)
36. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci US A. 1994;91: 3974-3978. (Pubitemid 24139555)
37. Kondyli M, Gatzounis G, Kyritsis A, et al. Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors. J Neurooncol. 2010;100:157-164.
38. Sanchez PE, Navarro FP, Fares RP, et al. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span. J Comp Neurol. 2009;514:403-414.
39. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90-95. (Pubitemid 40066704)
40. Jelkmann W, Bohlius J, Hallek M, et al. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67:39-61.
41. Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb VascBiol. 1999;19:1518-1525. (Pubitemid 29263023)
42. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998;9:397-405. (Pubitemid 28495548)
43. Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol. 1996;271(1 Pt 1):E113-E122.
44. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc NatlAcad Sci USA. 2001;98:4044-4049. (Pubitemid 32249895)
45. Siren AL, Fasshauer T, Bartels C, et al. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 2009;6:108-127.
46. Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 1997;76:105-116. (Pubitemid 26407940)
47. Genc S, Kuralay F, Genc K, et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett. 2001;298:139-141. (Pubitemid 32037074)
48. Hardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther. 2006;5:356-361.
49. Solar P, Koval J, Mikes J, et al. Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol Cancer Ther. 2008; 7:2263-2271.
50. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619. (Pubitemid 23259742)
51. Li D, Yang B, Mehta JL. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am JPhysiol. 1998;275(2 Pt 2):H568-H576.
52. Salvayre R, Auge N, Benoist H, et al. Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta. 2002;1585:213-221. (Pubitemid 36092085)
53. Napoli C, Quehenberger O, De Nigris F, et al. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000;14:1996-2007.
54. Saxena A, McMeekin JD, Thomson DJ. Expression of Bcl-x, Bcl-2, Bax, and Bak in endarterectomy and atherectomy specimens. J Pathol. 2002; 196:335-342. (Pubitemid 34189424)
55. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res. 1993;27:1233-1236. (Pubitemid 23250902)
56. Haller H, Christel C, Dannenberg L, et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996;50:481-488. (Pubitemid 26274375)
57. Ammarguellet F, Llovera M, Kelly PA, et al. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2001;284:1031-1038. (Pubitemid 32924752)
58. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. NEngl J Med. 2006; 355:2071-2084. (Pubitemid 44749316)